Biological agents represent a valid therapeutic option in patients with severe and/or relapsing vasculitis. Over the last years, some of these agents have become an established therapy (such as RTX in AAV or IFX for ocular BD), and some appear to hold promise to become so. In addition, there are a number of drugs in the pipeline that may contribute to further improve the prognosis of vasculitis. As the range of medications available for vasculitis widens, the need will also increase to define the best treatment schemes as well as to identify those patients that may benefit most from biological agents.

Biologics in vasculitides: Where do we stand, where do we go from now? / Pazzola, Giulia; Muratore, Francesco; Pipitone, Nicolò; Salvarani, Carlo. - In: LA PRESSE MÉDICALE. - ISSN 0755-4982. - ELETTRONICO. - 44:6 Part 2(2015), pp. e231-e239. [10.1016/j.lpm.2015.04.010]

Biologics in vasculitides: Where do we stand, where do we go from now?

MURATORE, Francesco;SALVARANI, CARLO
2015

Abstract

Biological agents represent a valid therapeutic option in patients with severe and/or relapsing vasculitis. Over the last years, some of these agents have become an established therapy (such as RTX in AAV or IFX for ocular BD), and some appear to hold promise to become so. In addition, there are a number of drugs in the pipeline that may contribute to further improve the prognosis of vasculitis. As the range of medications available for vasculitis widens, the need will also increase to define the best treatment schemes as well as to identify those patients that may benefit most from biological agents.
27-mag-2015
44
6 Part 2
e231
e239
Biologics in vasculitides: Where do we stand, where do we go from now? / Pazzola, Giulia; Muratore, Francesco; Pipitone, Nicolò; Salvarani, Carlo. - In: LA PRESSE MÉDICALE. - ISSN 0755-4982. - ELETTRONICO. - 44:6 Part 2(2015), pp. e231-e239. [10.1016/j.lpm.2015.04.010]
Pazzola, Giulia; Muratore, Francesco; Pipitone, Nicolò; Salvarani, Carlo
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S075549821500202X-main.pdf

non disponibili

Tipologia: Versione dell'editore (versione pubblicata)
Dimensione 439.58 kB
Formato Adobe PDF
439.58 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/1079759
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 2
social impact